Related Experiment Video
Updated: Jun 26, 2026
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Anticoagulation in atrial fibrillation - an update]
Matthias Antz1, Bettina Hullmann, Christian Neufert
1Ltd. Arzt Elektrophysiologie, Klinik für Kardiologie Herz- und Gefässzentrum, Klinikum Oldenburg gGmbH, Rahel-Straus-Strasse 10, 26133 Oldenburg. antz.matthias@klinikum-oldenburg.de
Herz
|January 13, 2009
Summary
Effective anticoagulation is crucial for preventing thromboembolic events in atrial fibrillation patients. This article simplifies current guideline recommendations for anticoagulation therapy.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Context:
- Atrial fibrillation (AF) poses a significant risk for thromboembolic events.
- Current anticoagulation practices in AF patients often deviate from established guidelines.
- Optimizing anticoagulation is essential for patient outcomes.
Purpose:
- To simplify and summarize current guidelines for anticoagulation in atrial fibrillation.
- To provide clear recommendations for anticoagulation management in various AF scenarios.
- To improve adherence to evidence-based anticoagulation strategies.
Summary:
- The article outlines simplified guidelines for anticoagulation in atrial fibrillation.
- Recommendations cover chronic anticoagulation, post-cardioversion, and post-ablation scenarios.
- Focus is on making anticoagulation indications more straightforward for clinicians.
Impact:
- Aims to increase the proportion of AF patients receiving guideline-adherent anticoagulation.
- Expected to reduce thromboembolic events and improve patient safety.
- Facilitates better clinical decision-making in AF management.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...